Guardant Health announces patient enrollment in Vanguard Study

Guardant Health (GH) announced that patient enrollment has begun in the National Cancer Institute’s Vanguard Study to evaluate emerging multi-cancer detection technology. Guardant’s Shield MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests-blood tests that can screen for several types of cancer simultaneously-in future randomized controlled trials. The Vanguard Study, conducted by the Cancer Screening Research, a new NCI-sponsored clinical trials network, is enrolling individuals ages 45-75 who do not currently have cancer and who have not received a cancer diagnosis in the past five years. All participants will be offered standard cancer screenings as part of their care. Results from the study will inform the design of a much larger randomized controlled trial to evaluate the use of MCD tests for cancer screening.